Bioventus has entered an agreement to acquire Misonix for $518 million in a cash-and-stock transaction.
Once the transaction closes, Misonix will operate under Bioventus. The deal is expected to accelerate Misonix's BoneScalpel and Nexus adoption and extend its international access. The acquisition will also augment Bioventus' lower extremity offerings and commercial footprint.
"We believe this acquisition will accelerate our growth opportunities, enhance our double-digit revenue growth and provide a significant opportunity for long-term margin expansion," Bioventus CEO Ken Reali said in a July 29 news release. "The combination with Misonix will create significant value for our shareholders and enable us to better serve our customers with more comprehensive solutions and a broader portfolio."
Bioventus said it expects the acquisition to add almost $80 million in revenue in 2021.
The deal is expected to close in the fourth quarter.